Publications by authors named "Katy Milne"

40Publications

The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.

Gynecol Oncol 2020 Jul 20;158(1):167-177. Epub 2020 May 20.

Deeley Research Centre, BC Cancer, Victoria, BC V8R 6V5, Canada; Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC V8P 3E6, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z3, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2020.04.689DOI Listing
July 2020

Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.

Clin Cancer Res 2019 Apr 6;25(8):2537-2548. Epub 2018 Dec 6.

Departments of Gynecology and Obstetrics, and University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3241DOI Listing
April 2019

PD-L1 and intratumoral immune response in breast cancer.

Oncotarget 2017 Aug 30;8(31):51641-51651. Epub 2017 May 30.

Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.18305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584276PMC
August 2017

CD103 and Intratumoral Immune Response in Breast Cancer.

Clin Cancer Res 2016 Dec 7;22(24):6290-6297. Epub 2016 Jun 7.

Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0732DOI Listing
December 2016

CD74 and intratumoral immune response in breast cancer.

Oncotarget 2017 Feb;8(8):12664-12674

Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.8610DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355043PMC
February 2017

PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.

Gynecol Oncol 2016 05 16;141(2):293-302. Epub 2016 Mar 16.

Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada; Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.03.008DOI Listing
May 2016

Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer.

Clin Cancer Res 2016 06 13;22(12):3005-15. Epub 2016 Jan 13.

Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada. Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada. Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2762DOI Listing
June 2016

PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.

Cancer Immunol Res 2015 Aug 8;3(8):926-35. Epub 2015 May 8.

Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada. Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada. Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0239DOI Listing
August 2015

Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8 tumor-infiltrating lymphocytes in ovarian cancer.

Oncoimmunology 2014 10;3:e27668. Epub 2014 Jan 10.

Trev and Joyce Deeley Research Centre; British Columbia Cancer Agency; Victoria, BC Canada ; Department of Biochemistry and Microbiology; University of Victoria; Victoria, BC Canada ; Department of Medical Genetics; University of British Columbia; Vancouver, BC Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.27668DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4121334PMC
January 2014

Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer.

Clin Cancer Res 2014 Mar 9;20(5):1125-34. Epub 2013 Dec 9.

Authors' Affiliations: Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency; Department of Biochemistry and Microbiology, University of Victoria, Victoria; Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver; Departments of Medical Genetics and Pathology and Laboratory Medicine, University of British Columbia, Vancouver; and Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2147DOI Listing
March 2014

Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.

Clin Cancer Res 2014 Jan 4;20(2):434-44. Epub 2013 Nov 4.

Authors' Affiliations: Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency; Department of Biochemistry and Microbiology, University of Victoria; Departments of Pathology and Laboratory Medicine and Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/20/2/434.full.
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-1877DOI Listing
January 2014

Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease.

J Pathol 2013 Mar 29;229(4):515-24. Epub 2012 Nov 29.

BC Cancer Agency, Michael Smith Genome Sciences Centre, 675 West 10th Avenue, Vancouver, BC, V5Z 1 L3, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4105DOI Listing
March 2013

CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.

Clin Cancer Res 2012 Jun 2;18(12):3281-92. Epub 2012 May 2.

Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-0234DOI Listing
June 2012

BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.

Mod Pathol 2012 May 27;25(5):740-50. Epub 2012 Jan 27.

Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2011.211DOI Listing
May 2012

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

Breast Cancer Res 2011 8;13(6):R126. Epub 2011 Dec 8.

Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, V8R 6V5, Canada.

View Article

Download full-text PDF

Source
http://breast-cancer-research.biomedcentral.com/articles/10.
Publisher Site
http://dx.doi.org/10.1186/bcr3072DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326568PMC
June 2012

Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR).

Breast Cancer (Auckl) 2011 31;5:105-15. Epub 2011 May 31.

Deeley Research Centre, Vancouver Island Cancer Centre, British Columbia Cancer Agency, 2410 Lee Avenue, Victoria, BC, Canada, V8R 6V5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BCBCR.S7344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117626PMC
July 2011

Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.

Gynecol Oncol 2010 Sep 11;118(3):228-36. Epub 2010 Jun 11.

Trev and Joyce Deeley Research Centre, BC Cancer Agency, Victoria, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2010.05.016DOI Listing
September 2010

Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model.

Breast Cancer Res Treat 2010 Jun 30;121(3):753-63. Epub 2009 Sep 30.

Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, 2410 Lee Avenue, Victoria, BC V8R 6V5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-009-0559-yDOI Listing
June 2010

Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene.

Cancer Immunol Immunother 2009 Nov 7;58(11):1865-75. Epub 2009 Apr 7.

Trev and Joyce Deeley Research Centre, British Columbia Cancer Agency, 2410 Lee Avenue, Victoria, BC V8R 6V5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-009-0698-3DOI Listing
November 2009

CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.

Clin Cancer Res 2007 Dec;13(23):7172-80

Deeley Research Centre, British Columbia Cancer Agency, University of Victoria, Victoria, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-07-1724DOI Listing
December 2007

Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells.

Cancer Res 2007 Jul;67(13):6442-50

Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-0622DOI Listing
July 2007